Implementation of standardized clinical outcomes across multiple specialty pharmacy (SpRx) patient management program disease states and disease activity assessments

PRESENTER:

Carolyn Faylor PharmD

BACKGROUND:

- Disease Activity Assessments (DAA) are frequently collected to monitor disease progression and treatment effectiveness
- Creating outcome metrics to programmatically describe multiple types of DAA results can be complex due relevant event sequencing, longitudinal management & incompleteness
  - ❖ **Herein we describe the methodology to report standardized metrics across any DAA type with SpRx management present**

METHODS

1. Patient reported results for PAS-II (RA), SCCAI, HBI (GI/IBD) and migraine free days were implemented into applicable SpRx workflows by 7.2024
   - ❑ Minimum frequency every 3 months
   - ❑ Not all SpRx patients received DAA; clinic and SpRx workflow specific
2. Epic ® / Compass Rose™ program-based data
   - ❑ Date of enrollment, disenrollment, declined or ineligible
3. Disease state dataset with merged DAA results in sequence to SpRx management
4. Each dataset appended into composite analytical dataset with standardized SpRx program-based metrics:
   - Baseline DAA performed at enrollment±56 days, if recent DAA performed prior
   - Percent of Programs with 2+ DAA results
   - Percent Change from baseline value
   - Change in DAA Category from baseline
5. All data manipulation was performed in Stata18 and visualizations via Tableau

University of Nebraska Medical Center

Clinical outcome metrics standardized across disease states and DAA types can be leveraged to share results concisely with stakeholders

Append each subset

All pairwise combinations

ID	Date of Enrollment	Date of Disenrollment	Program
1	7/1/2024	NULL	Migraine
2	9/1/2025	9/9/2026	Migraine
3	12/1/2025	12/7/2025	Migraine

ID	DAA Date	DAA Value
1	7/1/2024	X
1	10/1/2024	Y
2	12/1/2026	Z
3	12/6/2025	A
3	1/1/2026	B
3	4/4/2026	C
4	7/2/2024	D

ID	Date of Enrollment	Date of Disenrollment	Program	DAA Date	DAA Value	SpRx eligible	Seq.
1	7/1/2024	NULL (Active)	Migraine	7/1/2024	X	Yes	1
1	7/1/2024	NULL (Active	Migraine	10/1/2024	Y	Yes	2
2	9/1/2025	9/9/2026	Migraine	12/1/2026	Z	No	1
3	12/1/2025	12/7/2025	Migraine	12/6/2025	A	Yes	1
3	12/1/2025	12/7/2025	Migraine	1/1/2026	B	No	2
3	12/1/2025	12/7/2025	Migraine	4/4/2026	C	No	3
4	NULL (Non-SpRx DAA)		N/a	7/2/2024	D	No	n/a
5	8/1/2024	NULL (Active)	**RA**	12/1/2026	E	Yes	1
5	8/1/2024	NULL (Active)	**RA**	12/6/2025	F	Yes	2
6	9/2/2025	1/1/2025	GI/IBD	1/1/2026	G	No	1
7	7/1/2024	NULL (Active)	GI/IBD	4/4/2026	H	Yes	1



Results presented by:

- Total SpRx
- By individual Program Name or DAA Type
- At end of QTR/FY or cross-sectional at date of DAA performed
- **Includes pharmacist and provider collected DAA values applicable to SpRx services management**

RESULTS

- Baseline DAA completed at enrollment ± 56 days



- Percent of programs with 2+ DAA results



- Mean Percent Change in DAA value from baseline



- Change in DAA Category from Baseline



Anthony Donovan PharmD, MPH, Carolyn Faylor PharmD, Louie Dunn PharmD, BCPS, Carrie Nixon PharmD, Marysa Heisterkamp PharmD, BCPS, Victoria McCarthy, PharmD BCACP, Randall Moore PharmD

1) Nebraska Medicine, Community-Based Pharmacy Operations Omaha, NE

Nebraska Medicine